Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2003;Recommandations de la Société Canadienne de thoracologie relativement au traitement de la maladie pulmonaire obstructive chronique - 2003

Canadian Respiratory Journal

Volumn 10, Issue SUPPL. A, 2003, Pages

  O'Donnell, Denis E ^a   Aaron, Shawn ^b   Bourbeau, Jean ^c   Hernandez, Paul ^d   Marciniuk, Darcy ^e   Balter, Meyer ^f   Ford, Gordon ^g   Gervais, Andre ^h   Goldstein, Roger ^f   Hodder, Rick ^b   Maltais, Francois ⁱ   Road, Jeremy ^j  

^a QUEEN S UNIVERSITY   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d DALHOUSIE UNIVERSITY   (Canada)

^e UNIVERSITY OF SASKATCHEWAN   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

^g UNIVERSITY OF ALBERTA   (Canada)

^h UNIVERSITÉ DE MONTRÉAL   (Canada)

ⁱ UNIVERSITÉ LAVAL   (Canada)

^j UNIVERSITY OF BRITISH COLUMBIA   (Canada)

more..

Author keywords

Chronic obstructive pulmonary disease; Management; National guidelines

Indexed keywords

ALPHA 1 ANTITRYPSIN; AMINOPENICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; BECLOMETASONE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE; CEPHALOSPORIN DERIVATIVE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; FLUTICASONE; FORMOTEROL; INFLUENZA VACCINE; IPRATROPIUM BROMIDE; MACROLIDE; METHYLXANTHINE; OXYGEN; PLACEBO; PNEUMOCOCCUS VACCINE; PREDNISONE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SALBUTAMOL; SALMETEROL; STEROID; THEOPHYLLINE DERIVATIVE;

ALPHA 1 ANTITRYPSIN DEFICIENCY; ANTIBIOTIC THERAPY; CANADA; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; CLINICAL TRIAL; DISEASE EXACERBATION; DISEASE SEVERITY; EARLY DIAGNOSIS; ENDOCRINE DISEASE; EVIDENCE BASED MEDICINE; EXERCISE; EYE DISEASE; GASTROINTESTINAL DISEASE; HEALTH ECONOMICS; HUMAN; LUNG TRANSPLANTATION; MEDICAL SOCIETY; MENTAL DISEASE; MORBIDITY; MORTALITY; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; OXYGEN THERAPY; PATIENT CARE; PHYSICAL ACTIVITY; PHYSICAL DISABILITY; POSITIVE END EXPIRATORY PRESSURE; PRACTICE GUIDELINE; PRESCRIPTION; PREVENTIVE MEDICINE; PRIORITY JOURNAL; PUS; QUALITY OF LIFE; RECURRENT DISEASE; RESPIRATORY TRACT DISEASE; REVIEW; RISK ASSESSMENT; SKIN DISEASE; SMOKING CESSATION; SPIROMETRY; STEROID THERAPY; SYMPTOMATOLOGY; TREATMENT PLANNING; URINARY TRACT DISEASE; XEROSTOMIA;

EID: 0041695175     PISSN: 11982241     EISSN: None     Source Type: Journal    
DOI: 10.1155/2003/567598     Document Type: Review

References (267)

1. Canadian Asthma Consensus Conference: Summary of recommendations. Can Respir J 1996;3:89-100.
2. Debigaré R, Côté CH, Maltais F. Peripheral muscle wasting in chronic obstructive pulmonary disease: Clinical relevance and mechanisms. Am J Respir Crit Care Med 2001;164:1712-7.
3. Klinger JR, Hill NS. Right ventricular dysfunction in chronic obstructive pulmonary disease. Chest 1991;99:715-23.
4. Stradling JR, Lane DJ. Development of secondary polycythemia in chronic airways obstruction. Thorax 1981;34:777-82.
5. Foley RJ, ZuWallack R. The impact of nutritional depletion in chronic obstructive pulmonary disease. J Cardiopulm Rehabil 2001;21:288-95.
6. Lacasse Y, Rousseau L, Maltais F. Prevalence and impact of depression in patients with severe chronic obstructive pulmonary disease. J Cardiopulm Rehabil 2001;21:80-6.
7. American Thoracic Society. Lung function testing: Selection of reference values and interpretative strategies. Am Rev Respir Dis 1991;144:1202-18.
8. The Centre for Chronic Disease Prevention and Control, Health Canada, Canadian Institute for Health Information. Editorial Board Respiratory Disease in Canada. Ottawa: Health Canada, 2003.
9. Ernst PP, Bourbeau J, Rainville B, Benayoun S, Suissa S. Underestimation of COPD as a cause of death. Eur Respir J 2000;16(Suppl 31):13S.
10. Calverley P, Bellamy D. The challenge of providing better care for patients with chronic obstructive pulmonary disease: The poor relation of airway obstruction. Thorax 2000;55:78-82.
11. Mullen JB, Wright JL, Wiggs BR, Pare PD, Hogg JC. Reassessment of inflammation of airways in chronic bronchitis. Br Med J 1985;291:1235-9.
12. Cosio M, Ghezzo H, Hogg JC, et al. The relations between structural changes in small airways and pulmonary-function tests. N Engl J Med 1978;298:1277-81.
13. Niewoehner DE, Kleinerman J, Rice DB. Pathologic changes in the peripheral airways of young cigarette smokers. N Engl J Med 1974;291:755-8.
14. Wright JL, Lawson LM, Pare PD, Wiggs BJ, Kennedy S, Hogg JC. Morphology of peripheral airways in current smokers and ex-smokers. Am Rev Respir Dis 1983;127:474-7.
15. Ollerenshaw SL, Woolcock AJ. Characteristics of the inflammation in biopsies from large airways of subjects with asthma and subjects with chronic airflow limitation. Am Rev Respir Dis 1992;145:922-7.
16. Hunninghake GW, Crystal RG. Cigarette smoking and lung destruction: Accumulation of neutrophils in the lungs of cigarette smokers. Am Rev Respir Dis 1983;128:833-8.
17. Shapiro SD. End-stage chronic obstructive pulmonary disease. The cigarette is burned out but inflammation rages on. Am J Respir Crit Care Med 2001;164:339-40,
18. O'Shaughnessy TC, Ansari TW, Barnes NC, Jeffrey PK. Inflammation in bronchial biopsies of subjects with chronic bronchitis: Inverse relationship of CD8+ T lymphocytes with FEV1. Am J Respir Crit Care Med 1997;155:852-7.
19. Saetta M, DiStefano A, Maestrelli P, et al. Activated T-lymphocytes and macrophages in bronchial mucosa of subjects with chronic bronchitis. Am Rev Respir Dis 1993;147:301-6.
20. Saetta M, Di Stefano A, Turato G, et al. CD8+ T-lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:822-6.
21. Leopold JG, Geoff J. Centrilobular form of hypertrophic emphysema and its relation to chronic bronchitis. Thorax 1957;12:219-35.
22. McLean KA. Pathogenesis of pulmonary emphysema. Am J Med 1958;25:62-74.
23. Repine JE, Bast A, Lankhorst I. Oxidative stress in chronic obstructive pulmonary disease. Oxidative Stress Study Group. Am J Respir Crit Care Med 1997;156:341-57.
24. MacNee W. Pathophysiology of cor-pulmonale in chronic obstructive pulmonary disease. Part Two. Am J Respir Crit Care Med 1994;150:1158-68.
25. O'Donnell DE, Webb K. Exertional breathlessness in patients with CAL: The role of lung hyperinflation. Am Rev Respir Dis 1993;48:1351-7.
26. O'Donnell DE, Revill S, Webb KA. Dynamic hyperinflation and exercise intolerance in COPD. Am J Respir Crit Care Med 2001;164:770-7.
27. Tantucci C, Duguet A, Similowski T, Zelter M, Derenne JP, Milic-Emili J. Effect of salbutamol on dynamic hyperinflation in chronic obstructive pulmonary disease patients. Eur Respir J 1998;12:799-804.
28. Enright PL, Crapo RO. Controversies in the use of spirometry for early recognition and diagnosis of chronic obstructive pulmonary disease in cigarette smokers. Clin Chest Med 2000;21:645-52.
29. Mclvor RA, Tashkin DP. Underdiagnosis of chronic obstructive pulmonary disease: A rationale for spirometry as a screening tool. Can Respir J 2001;8:153-8.
30. Eaton TS, Withy JE, Garrett J, Mercer R, Whitlock M, Rea HH. Spirometry in primary care practice: The importance of quality assurance and the impact of spirometry workshops. Chest 1999;116:416-23.
31. Hepper NG, Drage CW, Davies SF, et al. Chronic obstructive pulmonary disease: A community-oriented program including professional education and screening by a voluntary health agency. Am Rev Respir Dis 1980;121:97-104.
32. Stewart AL, Greenfield S, Hays RD, et al. Functional status and well-being of patients with chronic conditions. Results from the Medical Outcomes Study. JAMA 1989;262:907-13.
33. Fletcher CM, Elmes PC, Wood CH. The significance of respiratory symptoms and the diagnosis of chronic bronchitis in a working population. Br Med J 1959;1:257-66.
34. Ferrer M, Alonso J, Morera J, et al. Chronic obstructive pulmonary disease and health-related quality of life. Ann Intern Med 1997;127:1072-9.
35. Nishimura K, Izumi T, Tsukino M, et al. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest 2002;121:1434-40.
36. The COPD Committee Group of the Standards of Care Committee of the BTS. BTS guidelines for the management of chronic obstructive pulmonary disease. Thorax 1997;52:S1-28.
37. Pauwels RA, Buist SA, Calverley PMA, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop Summary. Am J Respir Crit Care Med 2001;163:1256-76.
38. Oga T, Nishimura K, Tsukino M, Sato S, Hajiro T. Analysis of the factors related to mortality in chronic obstructive pulmonary disease: Role of exercise capacity and health status. Am J Respir Crit Care Med 2003;167:544-9.
39. Callahan CM, Dittus RS, Katz BP. Oral corticosteroid therapy for patients with stable chronic obstructive pulmonary disease. A meta-analysis. Ann Intern Med 1991;114:216-23.
40. Burge PS, Caverley PM, Jones PW, Spencer S, Andersen JA, Maslen TK. Randomized, double blind, placebo controlled study of fluticasone propitionate in patients with moderate to severe chronic obstructive pulmonary disease: The ISOLDE trial. BMJ 2000;320:1297-303.
41. Boothman-Burrell D, Delany SG, Flannery EM, Hancox RJ, Taylor DR. The efficacy of inhaled corticosteroids in the management of non-asthmatic chronic airflow obstruction. N Z Med J 1997;110:370-3.
42. Wolkove N, Dajczman E, Colacone A, Kreisman H. The relationship between pulmonary function and dyspnea in obstructive lung disease. Chest 1989;96:1247-51.
43. Bauerle O, Chrusch CA, Younes M. Mechanisms by which COPD affects exercise tolerance. Am J Resp Crit Care Med 1998;157:57-68.
44. Belman MJ, Botnick WC, Shin JW. Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease. Am J Resp Crit Care Med 1996;153:967-75.
45. O'Donnell DE, Lam M, Webb KA. Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;158:1557-65.
46. Newton M, O'Donnell DE, Forkert L. Response of lung volumes to inhaled salbutamol in a large population of patients with severe hyperinflation. Chest 2002;121:1042-50.
47. O'Donnell DE, Forkert L, Webb KA. Evaluation of bronchodilator responses in patients with "irreversible" emphysema. Eur Respir J 2001;18:914-20.
48. Oga T, Nishimura K, Tsukino M, Hajiro T, Ideda A, Izumi T. The effects of oxitropium bromide on exercise performance in patients with stable chronic obstructive pulmonary disease. A comparison of three different exercise tests. Am J Resp Crit Care Med 2000;161:1897-901.
49. Mahler DA, Weinberg DH, Wells CK, Feinstein AR. The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 1984;85:751-8.
50. Guyatt GH, Berman LB, Townsend M, Pugsley SO, Chambers LW. A measure of quality of life for clinical trials in chronic lung disease. Thorax 1987;42:773-8.
51. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation. Am Rev Respir Dis 1992;145:1321-7.
52. Ries AL, Kaplan RM, Limberg TM, Prewitt LM. Effects of pulmonary rehabilitation on physiologic and psychosocial outcomes in patients with chronic obstructive pulmonary disease. Ann Intern Med 1995;122:823-32.
53. Bourbeau J, Julien M, Maltais F, et al. Reduction of hospital utilization in patients with chronic obstructive pulmonary disease: A disease-specific self-management intervention. Arch Intern Med 2003;163:585-91.
54. Gallefoss F, Bakke PS. Impact of patient education and self-management on morbidity in asthmatics and patients with chronic obstructive pulmonary disease. Respir Med 2000;94:279-87.
55. Worth H. Self management in COPD: One step beyond? Patient Educ Couns 1997;32(1 Suppl):S105-9.
56. Gallefoss F, Bakke PS. Cost-benefit and cost-effectiveness analysis of self-management in patients with COPD - A 1-year follow-up randomized, controlled trial. Respir Med 2002;96:424-31.
57. Statistics Canada. National Population Health Survey 2000-2001.
58. Anthonisen NR, Connett JE, Murray RP, for the Lung Health Study Research Group. Smoking and lung function of lung health study participants after 11 years. Am J Respir Crit Care Med 2002;166:675-9.
59. Kanner RE, Connett JE, Williams DE, Buist SA. Effects of randomized assignment to a smoking cessation intervention and changes in smoking habits on respiratory symptoms in smokers with early chronic obstructive pulmonary disease: The Lung Health Study. Am J Med 1999;106:410-6.
60. Fiore MC, Bailey WC, Cohen SJ, et al. Treating tobacco use and dependence. Rockville, MD: US Department of Health and Human Services, Public Health Service, June 2000. (Version current at May 29, 2003).
61. Hurt RD, Sachs DPL, Glover ED, et al. A comparison of sustained-release Bupropion and placebo for smoking cessation. N Engl J Med 1997;337:1195-201.
62. Jorenby DE, Leischow SJ, Nides MA, et al. A controlled trial of sustained-release Bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999;340:685-91.
63. Nichol K, Margolis K, Wuorenma J, Von Sternberg T. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med 1994;331:179-93.
64. Nichol K, Baken L, Nelson A. Relation between influenza vaccination and outpatient visits, hospitalizations and mortality among elderly patients with chronic lung disease. Ann Intern Med 1999;130:397-403.
65. Butler J, Breiman R, Campbell J, Lipman H, Broome C, Facklam R. Pneuomococcal polysaccharide vaccine efficacy: An evaluation of current recommendations. JAMA 1993;270:1826-31.
66. Higgins BG, Powell RM, Cooper S, Tattersfield AE. Effect of salbutamol and ipratropium bromide on airway caliber and bronchial reactivity in asthma and chronic bronchitis. Eur Respir J 1991;4:415-20.
67. Shah SS, Johnston D, Woodcock AA, et al. Breathlessness and exercise tolerance in chronic airflow obstruction: 2-hourly versus 4-hourly salbutamol by inhalation. Curr Med Res Opin 1983;8:345-9.
68. Jaeschke R, Guyatt GH, Willan A, et al. Effect of increasing doses of β agonists on spirometric parameters, exercise capacity, and quality of life in patients with chronic airflow limitation. Thorax 1994;49:479-84.
69. Evald T, Keittelman S, Sindrup JH, et al. The effect of inhaled terbutaline on FEV1, FVC, dyspnoea and walking distance in patients with chronic obstructive lung disease. Respir Med 1992;86:93-6.
70. Hansen NC, May O. Domiciliary nebulized terbutaline in severe chronic airways obstruction. Eur Respir J 2002;3:463-4.
71. Guyatt A, Townsend M, Pugsley SO, et al. Effects on airway functions, exercise capacity, and quality of life. Am Rev Respir Dis 1987;135:1069-74.
72. COMBIVENT Inhalation Aerosol Study Group. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone: An 85-day multicenter trial. Chest 1994;105:1411-9.
73. Ikeda A, Nishimura K, Koyama H, Izumi T. Bronchodilating effects of combined therapy with clinical dosages of ipratropium bromide and salbutamol for stable COPD: Comparison with ipratropium bromide alone. Chest 1995;107:401-5.
74. Dahl R, Greefhorst LAPM, Nowak D, et al. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;164:778-84.
75. Ulrik CS. Efficacy of inhaled salmeterol in the management of smokers with chronic obstructive pulmonary disease, double-blind, placebo controlled, crossover study. Thorax 1995;50:750-4.
76. Boyd G, Morice AH, Pounsford JC, Seibert M, Peslis N, Crawford C. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD). Eur Respir J 1997;10:815-21.
77. Cazzola M, Matera MG, Santangelo G, Vinciguerra A, Rossi F, D'Amato G. Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: A dose-response study. Respir Med 1995;89:357-62.
78. Grove A, Lipworth BJ, Ried P, et al. Effects of regular salmeterol on lung function and exercise capacity in patients with chronic obstructive airways disease. Thorax 1996;51:689-93.
79. Goldkorn A, Diotto P, Burgess C, Weatherall M, Holt S, Beasley R. The pulmonary and extra-pulmonary effects of high dose formoterol Turbuhaler in COPD. Eur Respir J 2002.
80. Casaburi R, Mahler DA, Jones P, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002;19:217-24.
81. Vincken W, van Noord JA, Greefhorst APM, et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J 2002;19:209-16.
82. O'Donnell DE, Magnussen H, Aguilaniu B, Gerken F, Hamilton A, Fluege T. Spiriva (Tiotropium) improves exercise tolerance in COPD. Am J Resp Crit Care Med 2002;165:A227. (Abst)
83. Donohue JD, van Noord JA, Bateman ED, et al. A 6-month, placebo controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002;122:47-55.
84. Murciano D, Auclair M-H, Pariente R, Aubier M. A randomized, controlled trial of theophylline in patients with severe chronic obstructive pulmonary disease. N Engl J Med 1989;320:1521-5.
85. Mahon JL, Laupacis A, Hodder RV, et al. Theophylline for irreversible chronic airflow limitation: A randomized study comparing n of 1 trial to standard practice. Chest 1999;115:38-48.
86. Mahler DA, Matthay RA, Snyder PE, Wells CK, Loke J. Sustained-release theophylline reduces dyspnea in nonreversible obstructive airways disease. Am Rev Respir Dis 1985;131:22-5.
87. Dullinger D, Kronenberg R, Niewoehner DE. Efficacy of inhaled metaproterenol and orally-administered theophylline in patients with chronic airflow obstruction. Chest 1986;89:171-3.
88. Tsukino M, Nishimura K, Ideda A, et al. Effects of theophylline and ipratropium bromide on exercise performance in patients with stable chronic obstructive pulmonary disease. Thorax 1998;53:273.
89. ZuWallack RL, Mahler DA, Reilly D, et al. Salmeterol plus theophylline combination therapy in the treatment of COPD. Chest 2001;119:1661-70.
90. Vathenen AS, Britton JR, Ebden F, Cookson JB, Wharrad HJ, Tattersfield AE. High-dose inhaled albuterol in severe chronic airflow limitation. Am Rev Respir Dis 1988;138:850-5.
91. Gross NJ, Petty TL, Friedman M, Skorodin MS, Silvers W, Donohue JF. Dose response to ipratropium as a nebulized solution in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1989;139:1188-91.
92. Jenkins SC, Heaton RW, Fulton TJ, Moxham J. Comparison of domiciliary nebulized salbutamol and salbutamol from a metered-dose inhaler in stable chronic airflow limitation. Chest 1987;91:804-7.
93. Disse B. Antimuscarinic treatment for lung diseases. From research to clinical practice. Life Sci 2001;68:257-64.
94. Rice KL, Rubins JB, Lebahn F, et al. Withdrawal of chronic systemic corticosteroids in patients with COPD: A randomized trial. Am J Respir Crit Care Med 2000;162:174-8.
95. Chanez P, Vignola AM, O'Shaugnessy T, et al. Corticosteroid reversibility in COPD is related to features of asthma. Am J Respir Crit Care Med 1997;155:1529-34.
96. Pizzichini E, Pizzichini MM, Gibson PG, et al. Sputum eosinophilia predicts benefit from prednisone in smokers with chronic obstructive bronchitis. Am J Respir Crit Care Med 1998;158:1511-7.
97. Culpitt SV, Maziak W, Loukidis S, Nightingale JA, Matthews JL, Barnes PJ. Effects of high doses of inhaled steroids on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;160:1635-9.
98. David D, Grieco M, Cushman PJ. Adrenal glucocorticoids after 20 years: A review of their clinically relevant consequences. J Chron Dis 1970;22:637-711.
99. Lieberman P, Patterson R, Kunske R. Complications of long-term steroid therapy for asthma. Clin Immunol Immunopathol 1972;49:329-36.
100. McEvoy CE, Ensrud KE, Bender E, et al. Association between corticosteroid use and vertebral fractures in older men with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:704-9.
101. Decramer M, Lacquet LM, Fagard R, Rogiers P. Corticosteroids contribute to muscle weakness in chronic airflow obstruction. Am Rev Respir Dis 1994;150:11-6.
102. Biskobing DM. COPD and osteoporosis. Chest 2002;121:609-20.
103. Bourbeau J, Blais L, Sheehy O, LeLoier J. Inhaled corticosteroids among patients with COPD: Patterns and determinants of drug prescription. Eur Res J 2000;16:274S.
104. Keatings WM, Jatakanon A, Worsdell YM, Barnes PJ. Effects of inhaled and oral glucocortcoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med 1997;155:542-8.
105. Hattotuwa KL, Gizycki MJ, Ansari TW, Jeffery PK, Barnes NC. The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease. A double-blind, placebo controlled biopsy study. Am J Respir Crit Care Med 2002;165:1592-6.
106. Gizcki MJ, Hattotuwa KL, Barnes NC, Jeffery PK. Effects of fluticasone propionate on inflammatory cells in COPD: An ultrastructural examination of endobronchial biopsy tissue. Thorax 2002;57:799-803.
107. Alsaeedi A, Sin DD, McAlister FA. The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: A systematic review of randomized placebo-controlled trials. Am J Med 2002;113:59-65.
108. Paggiaro PL, Dahle R, Bakran I, Frith L, Hollingworth K, Efthimiou J. Multicentre randomized placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. Lancet 1998;351:773-80.
109. Pauwels RA, Lofdahl CG, Laitinen LA, et al, for the European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. N Engl J Med 1999;340:1948-53.
110. Vestbo J, Sorensen T, Lange F, Brix A, Torre P, Viskum K. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: A randomized controlled trial. Lancet 1999;353:1819-23.
111. Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000;343:1902-9.
112. Toogood J, Jennings B, Baskerville J, et al. Dosing regimen of budesonide and occurrence of oropharyngeal complications. Eur J Respir Dis 1984;65:35-44.
113. Toogood J, Jennings B, Greenway R, et al. Candidiasis and dysphonia complicating beclomethasone treatment of allergy. J Allergy Clin Immunol 1980;2:145-53.
114. Williams A, Baghat M, Stableforth D, et al. Dysphonia caused by inhaled steroids: Recognition of a characteristic laryngeal abnormality. Thorax 1983;38:813-21.
115. Egan JJ, Maden C, Adams JE, Eastell R, Woodcock AA. A randomized, double-blind study comparing the effects of beclomethasone and fluticasone on bone density over two years. Eur Respir J 1999;13:1267-75.
116. Li JTC, Ford LB, Chervinsky P, et al. Fluticasone propionate powder and lack of clinically significant effects on hypothalamic-pituitary-adrenal axis and bone mineral density over 2 years in adults with mild asthma. J Allergy Clin Immunol 1999;103:1062-8.
117. Garbe E, LeLorier J, Boivin JF, Suissa S. Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma. JAMA 1997;277:722-7.
118. Garbe E, Suissa S, LeLorier J. Association of inhaled corticosteroid use with cataract extraction in elderly patients. JAMA 1998;280:539-43.
119. Cumming RG, Mitchell P, Leeder SR. Use of inhaled corticosteroids and the risk of cataracts. N Engl J Med 1997;337:8-14.
120. Mahler DA, Wire P, Horstman D, Chang C-N, Shah T. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002;166:1084-91.
121. Calverley P, Pauwels R, Vestbo J, et al. Combining salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: A randomized controlled trial. Lancet 2003;361:449-56.
122. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Res J 2003;21:74-81.
123. Lacasse Y, Wong E, Guyatt GH, King D, Cook DJ, Goldstein RS. Meta-analysis of respiratory rehabilitation in chronic obstructive pulmonary disease. Lancet 1996;348:1115-9.
124. Lacasse Y, Brosseau L, Milne S, Wong E, Guyatt GH, Goldstein RS. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2002;3:CD003793.
125. American Thoracic Society. Pulmonary rehabilitation - 1999. Am J Respir Crit Care Med 1999;159:1666-82.
126. Maltais F, Leblanc P, Jobin J, et al. Intensity of training and physiologic adaptation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1997;155:555-61.
127. O'Donnell DE, McGuire M, Samis L, Webb KA. Effects of general exercise training on ventilatory and peripheral muscle strength and endurance in chronic airflow limitation. Am J Respir Crit Care Med 1998;157:1489-97.
128. Griffiths TL, Burr ML, Campbell IA, et al. Results at 1 year of outpatient multidisciplinary pulmonary rehabilitation: A randomized controlled trial. Lancet 2000;355:362-8.
129. Guell R, Casan P, Belda J, et al. Long-term effects of outpatient rehabilitation of COPD. A randomized trial. Chest 2000;117:976-83.
130. Troosters T, Gosselink R, Decramer M. Short- and long-term effects of outpatient rehabilitation in patients with chronic obstructive pulmonary disease: A randomized trial. Am J Med 2000;109:207-12.
131. Goldstein RS, Gort EH, Guyatt GH, Feeny D. Economic analysis of respiratory rehabilitation. Chest 1997;112:370-9.
132. Griffiths TL, Phillips CJ, Davies S, Burr ML, Campbell IA. Cost effectiveness of an outpatient multidisciplinary pulmonary rehabilitation programme. Thorax 2001;56:779-84.
133. Strijbos JH, Postma DS, van Altena R, Gimeno F, Koëter GH. A comparison between an outpatient hospital-based pulmonary rehabilitation program and a home-care pulmonary rehabilitation in patients with COPD. Chest 1996;109:366-72.
134. Ketelaars CA, Abu-Saad HH, Schlosser MA, Mostert R, Wouters EFM. Long-term outcome of pulmonary rehabilitation in patients with COPD. Chest 1997;112:363-9.
135. Engström CP, Persson LO, Larsson S, Sullivan M. Long-term effects of a pulmonary rehabilitation programme in outpatients with chronic obstructive pulmonary disease: A randomized controlled study. Scand J Rehabil Med 1999;31:207-13.
136. Foglio K, Bianchi L, Bruletti G, Battista L, Pagani M, Ambrosino N. Long-term effectiveness of pulmonary rehabilitation in patients with chronic airway obstruction. Eur Respir J 1999;13:125-32.
137. Berry MJ, Adair NE, Sevensky K, Quinby ALHM. Inspiratory muscle training and whole body reconditioning in chronic obstructive pulmonary disease: A controlled randomized trial. Am J Respir Crit Care Med 1996;153:1812-6.
138. Larson JL, Covey MK, Wirtz SE, et al. Cycle ergometer and inspiratory muscle training in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;160:500-7.
139. Ries AL, Ellis B, Hawkins RW. Upper extremity exercise training in chronic obstructive pulmonary disease. Chest 1988;93:688-92.
140. Martinez FJ, Vogel PD, Dupont DN, Stanopoulos I, Gray A, Beamis JF. Supported arm exercise vs unsupported arm exercise in the rehabilitation of patients with severe chronic airflow obstruction. Chest 1993;103:1397-402.
141. Schols AMWJ, Soeters PB, Mostert R, Pluymers RJ, Wouters EFM. Physiologic effects of nutritional support and anabolic steroids in patients with chronic obstructive pulmonary disease. A placebo-controlled randomized trial. Am J Respir Crit Care Med 1995;152:1268-74.
142. Ferreira IM, Brooks D, Lacasse Y, Goldstein RS. Nutritional support for individuals with COPD: A meta-analysis. Chest 2000;117:672-8.
143. Burdet L, de Muralt B, Schutz Y, Pichard C, Fitting JW. Administration of growth hormone to underweight patients with chronic obstructive pulmonary disease. A prospective, randomized, controlled study. Am J Respir Crit Care Med 1997;156:1800-6.
144. Brooks D, Lacasse Y, Goldstein RS. Pulmonary rehabilitation programs in Canada. A national survey. Am J Respir Crit Care Med 1998;157:A787. (Abst)
145. Medical Research Council Working Party. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Lancet 1981;i:681-6.
146. Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: A clinical trial. Ann Intern Med 1980;93:391-8.
147. Gorecka D, Gorzelak K, Siliwinski P, Tobiasz M, Zielinski J. Effect of long-term oxygen therapy on survival in patients with chronic obstructive pulmonary disease with moderate hypoxemia. Thorax 1997;52:674-9.
148. Fletcher EC, Luckett RA, Goodnight-White S, Miller CC, Qian W, Costarangos-Galarza C. A double blind trial of nocturnal supplemental oxygen for sleep desaturation in patients with chronic obstructive pulmonary disease and a daytime PaO2 above 60 mmHg. Am Rev Respir Dis 1992;145:1070-6.
149. Chaouat A, Weitzenblum E, Kessler R, et al. A randomized trial of nocturnal oxygen therapy in chronic obstructive pulmonary disease patients. Eur Respir J 1999;14:1002-8.
150. Cormick W, Olson LG, Hensley MJ, Saunders NA. Nocturnal hypoxaemia and quality of sleep in patients with chronic obstructive lung disease. Thorax 1986;41:846-54.
151. Fleetham J, West P, Mezon B, Conway W, Roth T, Kryger M. Sleep, arousals, and oxygen desaturation in chronic obstructive pulmonary disease. The effect of oxygen therapy. Am Rev Respir Dis 1982;126:429-33.
152. McKeon JL, Murree-Allen K, Saunders NA. Supplemental oxygen and quality of sleep in patients with chronic obstructive pulmonary disease. Thorax 1989;44:184-8.
153. Bye PT, Esau SA, Levy RD, et al. Ventilatory muscle function during exercise in air and oxygen in patients with chronic air-flow limitation. Am Rev Respir Dis 1985;132:236-40.
154. O'Donnell DE, D'Arsigny C, Webb KA. Effects of hyperoxia on ventilatory limitation during exercise in advanced chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163:892-8.
155. O'Donnell DE, Bain DJ, Webb KA. Factors contributing to relief of exertional breathlessness during hyperoxia in chronic airflow limitation. Am J Respir Crit Care Med 1997;155:530-5.
156. Matsuzawa Y, Kubo K, Fujimoto K, et al. Acute effects of oxygen on dyspnea and exercise tolerance in patients with pulmonary emphysema with only mild exercise-induced oxyhemoglobin desaturation. Nihon Kokyuki Gakkai Zasshi 2000;38:831-5.
157. Ishimini A, Saito H, Nishimura M, Nakano T, Miyamoto K, Kaawakami Y. Effect of supplemental oxygen on exercise performance in patients with chronic obstructive pulmonary disease and an arterial oxygen tension over 60 Torr. Nihon Kyobu Shikkan Gakkai Zasshi 1995;33:510-9.
158. Jolly EC, Di B, Aguirre VL, Luna CM, Berensztein S, Gene RJ. Effects of supplemental oxygen during activity in patients with advanced COPD without severe resting hypoxemia. Chest 2001;120:437-43.
159. Garrod R, Paul EA, Wedzicha JA. Supplemental oxygen during pulmonary rehabilitation in patients with COPD with exercise hypoxaemia. Thorax 2000;55:539-43.
160. Rooyackers JM, Dekhuijzen PN, Van Herwaarden CL, Folgering HT Training with supplemental oxygen in patients with COPD and hypoxaemia at peak exercise. Eur Respir J 1997;10:1278-84.
161. MacDonald CF, Blyth CM, Lazarus MD, Marschner I, Barter CE. Exertional oxygen of limited benefit in patients with chronic obstructive pulmonary disease and mild hypoxemia. Am J Respir Crit Care Med 1995;152:1616-9.
162. Mak MH, Bugler JR, Roberts CM, Spiro SG. Effect of arterial oxygen desaturation on six minute walk distance, perceived effort, and perceived breathlessness in patients with airflow limitation. Thorax 1993;48:33-8.
163. Tarpy SP, Celli BR. Long term oxygen therapy. N Engl J Med 1995;333:710-4.
164. Donner CF, Braghiroli A. When is liquid oxygen really needed? Monaldi Arch Chest Dis 1996;51:72-3.
165. Vergeret J, Brambilla C, Mounier L, et al. Portable oxygen therapy: Use and benefit in hypoxemic COPD patients on long term oxygen therapy. Eur Respir J 1989;2:20-5.
166. Anthonisen NR. Long term oxygen therapy. Ann Intern Med 1983;99:519-27.
167. Wedzicha JA. Ambulatory oxygen in chronic obstructive pulmonary disease. Monaldi Arch Chest Dis 1996;51:243-5.
168. Burrows B, Earle RH. Course and prognosis of chronic obstructive lung disease: A prospective study of 200 patients. N Engl J Med 1969;280:397-404.
169. Seemungal TA, Donaldson GC, Paul EA, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:1418-22.
170. Kanner RE, Anthonisen NR, Connet JE. Lower respiratory illnesses promote FEV1 decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;164:358-64.
171. Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest 2000;117(Suppl 2):398S-401S.
172. Mushlin AI, Black ER, Connolly CA, et al. The necessary length of hospital stay for chronic pulmonary disease. JAMA 1991;266:80-3.
173. Connors AF, Dawson NV, Thomas C, et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Am J Respir Crit Care Med 1996;154:959-67.
174. Burk RH, George RB. Acute respiratory failure in chronic obstructive pulmonary disease. Immediate and long-term prognosis. Arch Intern Med 1973;132:865-8.
175. Portier F, Defouilloy C, Muir JF, for the French Task Group for Acute Respiratory Failure in Chronic Respiratory insufficiency. Determinants of immediate survival among chronic respiratory insufficiency patients admitted to an intensive care unit for acute respiratory failure. A prospective multicenter study. Chest 1992;101:204-10.
176. Seneff MG, Wagner DP, Wagner RP, et al. Hospital and 1-year survival of patients admitted to intensive care units with acute exacerbation of chronic obstructive pulmonary disease. JAMA 1995;274:1852-7.
177. Cydulka RK, McFadden ER, J, Emerman CL, et al. Patterns of hospitalization in elderly patients with asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1997;156:1807-12.
178. Osman IM, Godden DJ, Friend JA, et al. Quality of life and hospital re-admission in patients with chronic obstructive pulmonary disease. Thorax 1997;52:67-71.
179. Emerman CL, Cydulka RK. Evaluation of high-yield criteria for chest radiography in acute exacerbation of chronic obstructive pulmonary disease. Ann Emerg Med 1993;22:680-4.
180. Tsai TW, Gallagher EJ, Lombardi G, et al. Guidelines for the selective ordering of admission chest radiography in adult obstructive airway disease. Ann Emerg Med 1993;22:1854-8.
181. Karpel JP, Pesin J, Greenberg D, et al. A comparison of the effects of ipratropium bromide and metaproterenol sulfate in acute exacerbations of COPD. Chest 1990;98:835-9.
182. Rebuck AS, Chapman KR, Abboud R, et al. Nebulized anticholinergic and sympathomimetic treatment of asthma and chronic obstructive airways disease in the emergency room. Am J Med 1987;82:59-64.
183. Zehner WJ Jr, Scott JM, Iannolo PM, Ungaro A, Terndrup TE. Terbutaline vs albuterol for out-of-hospital respiratory distress: Randomized, double-blind trial. Acad Emerg Med 1995;2:686-91.
184. Emerman CL, Cydulka RK. Effect of different albuterol dosing regimens in the treatment of acute exacerbation of chronic obstructive pulmonary disease. Ann Emerg Med 1997;29:474-8.
185. Maguire GP, Newman T, DeLorenzo LJ, Brown RB, Stone D. Comparison of a hand-held nebulizer with a metered dose inhaler-spacer combination in acute obstructive pulmonary disease. Chest 1991;100:1300-5.
186. Berry RB, Shinto RA, Wong FH, Despars JA, Light RW. Nebulizer vs spacer for bronchodilator delivery in patients hospitalized for acute exacerbations of COPD. Chest 1989;96:1241-6.
187. Greene AB Jr, Jackson CL. Terbutaline metered-dose inhalation vs metaproterenol by hand-held nebulization: A comparison in black inner-city COPD patients. J Natl Med Assoc 1988;80:393-6.
188. Higgins RM, Cookson WO, Chadwick GA. Changes in blood gas levels after nebuhaler and nebulizer administration of terbutaline in severe chronic airway obstruction. Bull Eur Physiopathol Respir 1987;23:261-4.
189. Summer W, Elston R, Tharpe L, Nelson S, Haponik EF. Aerosol bronchodilator delivery methods. Relative impact on pulmonary function and cost of respiratory care. Arch Intern Med 1989;149:618-23.
190. Emerman C, Connors A, Lukens T, et al. A randomized controlled trial of methylpredisolone in the emergency treatment of acute exacerbations of COPD. Chest 1989;95:563-7.
191. Albert R, Martin T, Lewis S. Controlled clinical trial of methylprednisolone in patients with chronic bronchitis and acute respiratory insufficiency. Ann Intern Med 1989;92:753-8.
192. Thompson W, Nielson C, Carvalho P, et al. Controlled trial of oral prednisone in outpatients with acute COPD exacerbation. Am J Respir Crit Care Med 1996;154:407-12.
193. Davies L, Angus R, Calverley P. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: A prospective randomized controlled trial. Lancet 1999;354:456-60.
194. Niewoehner D, Erbland M, Deupree R, et al, for the Department of Veterans Affairs Cooperative Study Group. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. N Engl J Med 1999;340:1941-7.
195. Anthonisen NR, Manfreda J, Warren CP, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987;106:196-204.
196. Elmes P, Fletcher C, Dutton A. Prophylactic use of oxytetracycline for exacerbations of chronic bronchitis. Br Med J 1957;2:1272-5.
197. Berry D, Fry J, Hindley C, et al. Exacerbations of chronic bronchitis treatment with oxytetracycline. Lancet 1960;1:137-9.
198. Fear EC, Edwards G. Antibiotic regimens in chronic bronchitis. Br J Dis Chest 1962;56:153-62.
199. Elmes P, King T, Langlands J, et al. Value of ampicillin in the hospital treatment of exacerbations of chronic bronchitis. Br Med J 1965;2:904-8.
200. Peterson E, Esmann V, Honcke P, et al. A controlled study of the effect of treatment on chronic bronchitis: An evaluation using pulmonary function tests. Acta Med Scand 1967;182:293-305.
201. Pines A, Raafat H, Plucinski K, Greenfield JS, Solari M. Antibiotic regimens in severe and acute purulent exacerbations of chronic bronchitis. Br Med J 1968;2:735-8.
202. Pines A, Raafat H, Greenfield J, et al. Antibiotic regimens in moderately ill patients with purulent exacerbations of chronic bronchitis. Br J Dis Chest 1972;66:107-15.
203. Nicotra MB, Rivera M, Awe RJ. Antibiotic therapy of acute exacerbations of chronic bronchitis. A controlled study using tetracycline. Ann Intern Med 1982;97:18-21.
204. Wilson R, Kubin R, Ballin I, et al. Five-day moxifloxacin therapy compared with 7-day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis. J Antimicrob Chemother 1999;44:501-13.
205. Chodosh S, Schreurs A, Siami G, et al, for the Bronchitis Study Group. Efficacy of oral ciprofloxacin vs clarithromycin for treatment of acute bacterial exacerbations of chronic bronchitis. Clin Infect Dis 1998;27:730-8.
206. Wilson R, Schentag J, Ball F, Mandell L. A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes. Clin Ther 2002;24:639-52.
207. Wilson R, Jones P, Schaberg T, et al. A clinical and outcomes assessment of the management of acute exacerbations of chronic bronchitis (AECB): The MOSAIC study. Poster P3371, 12th ERS Annual Congress, Stockholm, Sweden, September 2002.
208. Bott J, Carroll MP, Conway JH, et al. Randomized controlled trial of nasal ventilation in acute ventilatory failure due to chronic obstructive airways disease. Lancet 1993;341:1555-7.
209. Daskalopouou E, Tsara V, Fekete K, et al. Treatment of acute respiratory failure in COPD patients with positive pressure via nasal mask. Chest 1993;103:271S.
210. Servillo G, Ughi L, Rossano F, Leone D. Noninvasive mask pressure support ventilation in COPD patients. Intensive Care Med 1994;50:S54.
211. Brochard L, Mancebo J, Wysocki M, et al. Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease. N Engl J Med 1995;333:817-22.
212. Kramer N, Meyer TJ, Meharg J, et al. Randomized, prospective trial of noninvasive positive pressure ventilation in acute respiratory failure. Am J Respir Crit Care Med 1995;151:1799-806.
213. Angus RM, Ahmed MM, Fenwick LJ, et al. Comparison of the acute effects on gas exchange of nasal ventilation and doxapram in exacerbations of chronic obstructive pulmonary disease. Thorax 1996;51:1048-50.
214. Barbe F, Togores B, Rubi M, et al. Noninvasive ventilatory support does not facilitate recovery from acute respiratory failure in chronic obstructive pulmonary disease. Eur Respir J 1996;9:1240-5.
215. Ceikel T, Sungur M, Ceyhan B, et al. Comparison of noninvasive positive pressure ventilation with standard medical therapy in hypercapnic acute respiratory failure. Chest 1998;114:1636-42.
216. Andeev SN, Tret'iakov AV, Grigor'iants RA, et al. Study of the use of noninvasive ventilation of the lungs in acute respiratory insufficiency due to exacerbation of chronic obstructive pulmonary disease. Anesteziol Reanimatol 1998;3:45-51.
217. Confaloniere M, Potena A, Carbone G, et al. Acute respiratory failure in patients with severe community-acquired pneumonia: A prospective randomized evaluation of noninvasive ventilation. Am Respir Crit Care Med 1999;160:1585-91.
218. Martin TJ, Hovis JD, Costantino JP, et al. A randomized, prospective evaluation of noninvasive ventilation for acute respiratory failure. Am J Respir Crit Care Med 2000;161:807-13.
219. Plant PK, Owen JL, Elliott MW. Early use of non-invasive ventilation for acute exacerbations of chronic obstructive pulmonary disease on general respiratory wards: A multicentre randomized controlled trial. Lancet 2000;355:1931-5.
220. Keenan SP, Gregor J, Sibbald WJ, Cook D, Gafni A. Noninvasive positive pressure ventilation in the setting of severe, acute exacerbations of chronic obstructive pulmonary disease: More effective and less expensive. Crit Care Med 2000;28:2094-102.
221. Plant PK, Owen JL, Elliott MW. Non-invasive ventilation in acute exacerbations of chronic obstructive pulmonary disease: Long term survival and predictors of in-hospital outcome. Lancet 2001;56:708-12.
222. Soo Hoo GW, Santiago S, Williams A. Nasal mechanical ventilation for hypercapnic respiratory failure in chronic obstructive pulmonary disease: Determinants of success and failure. Crit Care Med 1994;22:1253-61.
223. Keenen SP, Powers C, McCormack DG. Noninvasive ventilation in milder COPD exacerbations: An RCT. Am J Respir Crit Care Med 2001;163:A250. (Abst)
224. Wijkstra PJ, Lacasse Y, Guyatt GH, Goldstein RS. Nocturnal non-invasive positive pressure ventilation for stable chronic obstructive pulmonary disease (Cochrane Review). In: The Cochrane Library, Issue 3, 2002. Oxford: Update Software.
225. Brantigan OC, Kress MB, Mueller EA. Surgical approach to pulmonary emphysema. Dis Chest 1961;39:483-51.
226. Cooper JD, Trulock EP, Trialitafillou AN, et al. Bilateral pneumonectomy (volume reduction) for chronic obstructive pulmonary disease. J Thorac Cardiovasc Surg 1995;109:106-19.
227. Cooper JD, Patterson GA, Sundaresen RS, et al. Results of 150 consecutive lung volume reduction procedures in patients with severe emphysema. J Thorac Cardiovasc Surg 1996;112:1319-30.
228. Cooper JD, Lefrak SS. Lung-reduction surgery: 5 years on. The Lancet 1999;353:26-7.
229. McKenna RJ, Brenner M, Fischel RJ, Gelb AF. Should volume reduction for emphysema be unilateral or bilateral? J Thorac Cardiovasc Surg 1996;112:1331-9.
230. McKenna RJ, Brenner M, Gelb AF. A randomized prospective trial of stapled lung reduction versus laser bullectomy for diffuse emphysema. J Thorac Cardiovasc Surg 1996;111:317-22.
231. Criner GJ, Cordova SC, Furukawa S, et al. Prospective randomized trial comparing bilateral lung volume reduction surgery to pulmonary rehabilitation in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;160:2021-7.
232. Goodnight-White S, Jones WJ, Baaklini J, et al. Prospective randomized controlled trial comparing bilateral lung volume reduction surgery (LVRS) to medical therapy alone in patients with severe emphysema. Chest 2000;118(Suppl 4):102S.
233. Lofdahl CG, Hillerdal G, Strom K. Randomized controlled trial of volume reduction surgery-preliminary results up to 12 months. Am J Respir Crit Care Med 2000:161:A585. (Abst)
234. Geddes D, Davies M, Koyama H, et al. Effects of lung volume reduction surgery in patients with severe emphysema. N Engl J Med 2000;343:239-45.
235. Pompeo E, Marino M, Nofroni I, et al. Reduction pneumoplasty versus respiratory rehabilitation in severe emphysema: A randomized study. Ann Thorac Surg 2000;70:948-54.
236. National Emphysema Treatment Trial Research Group. Patients at high risk of death after lung-volume-reduction surgery. N Engl J Med 2001;345:1075-83.
237. Hosenpud JD, Bennett LE, Keck BM, Boucek MM, Novick RJ. The Registry of the International Society for Heart and Lung Transplantation: Eighteenth Official Report - 2001. J Heart Lung Transplant 2001;20:805-15.
238. Arcasoy SM, Kotloff RM. Lung transplantation. N Engl J Med 1999;340:1081-91.
239. Hosenpud JD, Bennett LE, Keck BM, Edwards EB, Novick RJ. Effect of diagnosis on survival benefit of lung transplantation for end-stage lung disease. Lancet 1998;351:24-7.
240. Charman SC, Sharples LD, McNeil KD, Wallwork J. Assessment of survival benefit after lung transplantation by patient diagnosis. J Heart Lung Transplant 2002;21:226-32.
241. Maurer JR, Frost AE, Estenne M, Higgenbottam T, Glanville AR. International guidelines for the selection of lung transplant candidates. J Heart Lung Transplant 1998;17:703-9.
242. Levy RD, Ernst P, Levine SM, et al. Exercise performance after lung transplantation. J Heart Lung Transplant 1993;12:27-33.
243. Limbos MM, Joyce DP, Chan CK, Kesten S. Psychological functioning and quality of life in lung transplant candidates and recipients. Chest 2000;118:408-16.
244. Bennett LE, Keck BM, Daily OP, Novick RJ, Hosenpud JD. Worldwide thoracic organ transplantation: A report from the UNOS/ISHLT International Registry for Thoracic Organ Transplantation. Clin Transpl 2000:31-44.
245. Abboud RT, Ford GT, Chapman KR. Alpha1-antitrypsin deficiency: A position statement of the Canadian Thoracic Society. Can Respir J 2001;8:81-8.
246. Seersholm N, Wencker M, Banik N. Does α1-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary α1-antitrypsin deficiency? Eur Resp J 1997;10:2260-3.
247. The Alpha-1-Antitrypsin Deficiency Registry Study Group. Survival and FEV1 decline in individuals with severe deficiency of α1-antitrypsin. Am J Respir Crit Care Med 1998;158:49-59.
248. Dirksen A, Kijkman JH, Madsen F, et al. A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy. Am J Respir Crit Care Med 1999;160:1468-72.
249. Anthonisen NR, Wright EC, Hodgkin JE. Prognosis in chronic obstructive pulmonary disease. Am Rev Respir Dis 1986;133:14-20.
250. Schols AM, Slangen J, Volovics L, Wouters EF. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:1791-7.
251. Landbo C, Prescott E, Lange P, Vestbo J, Almdal TP. Prognostic value of nutritional status in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;160:1856-61.
252. Yohannes AM, Baldwin RC, Connolly M. Mortality predictors in disabling chronic obstructive pulmonary disease in old age. Age Ageing 2002;31:137-40.
253. McNeely PD, Hebert PC, Dales RE, et al. Deciding about mechanical ventilation in end-stage chronic obstructive pulmonary disease: How respirologists perceive their role. CMAJ 1997;156:177-83.
254. Dyspnea. Mechanisms, assessment, and management: a consensus statement. American Thoracic Society. Am J Respir Crit Care Med 1999;159:321-40.
255. Bruera E, Macmillan K, Pither J, MacDonald RN. Effects of morphine on the dyspnea of terminal cancer patients. J Pain Symptom Manage 1990;5:341-4.
256. Davis CL. ABC of palliative care. Breathlessness, cough, and other respiratory problems. BMJ 2997;315:931-4.
257. Heffner J. Chronic obstructive pulmonary disease. In: Curtis J, Rubenfield G, eds. Managing Death in the ICU: The Transition From Cure to Comfort. New York: Oxford University Press, 2000:319-28.
258. van Ede L, Yzermans CJ, Brouwer HJ. Prevalence of depression in patients with chronic obstructive pulmonary disease: A systematic review. Thorax 1999;54:688-92.
259. Barnes PJ. Novel approaches and targets for treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;160:S72-9.
260. Leckie MJ, Bryan SA, Hansel TT, et al. Novel therapy for COPD. Expert Opin Invest Drugs 2000;9:3-23.
261. Stockley RA. New approaches to the management of COPD. Chest 2000;117(Suppl 2):58S-62S.
262. Compton CH, Gubb J, Nieman R, et al, for the International Study Group. Cilomilast, a selective phosphodiesterase-4-inhibitor for treatment of patients with chronic obstructive pulmonary disease: A randomized, dose-ranging study. Lancet 2001;358:265-70.
263. Barnett MS, Underwood DC. New phosphodiesterase inhibitors as therapeutics for the treatment of chronic lung disease. Curr Opin Pulm Med 2000;6:164-9.
264. Dal Piaz V, Giovannoni MP. Phosphodiesterase 4 inhibitors, structurally unrelated to rolipram, as promising agents for the treatment of asthma and other pathologies. Eur J Med Chem 2000;35:463-80.
265. Mahler DA, Donohue JT, Barbee RA, et al. Efficacy of salmeterol xinofoate in the treatment of COPD. Chest 1999;115:957-65.
266. Jones PW, Bosh TK. Quality of life changes in COPD patients treated with salmeterol. Am J Resp Crit Care Med 1997;155:1283-9.
267. 2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163:1087-92.